Last 587.10
Change Today -18.50 / -3.05%
Volume 27.5K
RDHL On Other Exchanges
Symbol
Exchange
OTC US
Tel Aviv
As of 7:18 AM 02/1/15 All times are local (Market data is delayed by at least 15 minutes).

redhill biopharma ltd (RDHL) Snapshot

Open
$605.60
Previous Close
$605.60
Day High
$605.60
Day Low
$582.10
52 Week High
06/12/14 - $680.00
52 Week Low
11/18/14 - $295.00
Market Cap
516.0M
Average Volume 10 Days
101.5K
EPS TTM
$-0.11
Shares Outstanding
87.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REDHILL BIOPHARMA LTD (RDHL)

Related News

No related news articles were found.

redhill biopharma ltd (RDHL) Related Businessweek News

No Related Businessweek News Found

redhill biopharma ltd (RDHL) Details

RedHill Biopharma Ltd. is an Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. Its pipeline of proprietary products includes: RHB-104, an oral combination therapy for the treatment of Crohn's disease, with an ongoing Phase III study; RHB-105, an oral combination therapy for Helicobacter pylori infection, with an ongoing Phase III study; and RHB-102, a once-daily oral pill formulation of ondansetron for the prevention of nausea and vomiting in advanced stages of development for multiple indications. In addition, the company’s product pipeline includes RHB-106, an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; MESUPRON, a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; RP101, a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; RHB-103, an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA under FDA review; and RHB-101, a once-daily oral pill formulation of the cardio drug carvedilol. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.

8 Employees
Last Reported Date: 02/25/14
Founded in 2009

redhill biopharma ltd (RDHL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

redhill biopharma ltd (RDHL) Key Developments

RedHill Biopharma Ltd. Presents at 8th Annual OneMedForum 2015, Jan-12-2015

RedHill Biopharma Ltd. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 . Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.

RedHill Biopharma Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

RedHill Biopharma Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

RedHill Biopharma Ltd. Announces Acceptance for Review of BEKINDA™ European Marketing Application for Oncology Support

RedHill Biopharma Ltd. announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has validated the Marketing Authorization Application (MAA) for BEKINDA™ (RHB-102), a proprietary, extended-release, once-daily oral pill formulation of the antiemetic drug ondansetron indicated for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting (CINV and RINV, respectively), and initiated the formal review process for the application on December 30, 2014. The company expects to receive feedback from the MHRA regarding the MAA during the second half of 2015. With BEKINDA™, the company is targeting a considerable segment of the 5-HT3 oncology support antiemetic market, with estimated worldwide sales of approximately $940 million in 2031. The MAA was submitted to several member states under the European Decentralized Procedure, with the UK as the Reference Member State. The MAA submission followed a positive European Scientific Advice meeting with the UK MHRA and is backed by several pharmacokinetic studies which support the safety and efficacy of BEKINDA™ for prevention of nausea and vomiting following chemotherapy and radiotherapy treatments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDHL:IT 587.10 -18.50

RDHL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDHL.
View Industry Companies
 

Industry Analysis

RDHL

Industry Average

Valuation RDHL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REDHILL BIOPHARMA LTD, please visit www.redhillbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.